by David Wallace Patients Are Asking – Episode 1 In this interview with MPN specialist, Dr. Ghaith Abu-Zeinah, we learn what the term “disease modification” means. We discuss promising late-stage clinical trials and the importance of tracking your symptoms to discuss with your physician. David Wallace, PV Reporter, is your host and patient advocate. […]
Abstract: The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN). Activated JAK2 signaling by JAK2, CALR, and MPL mutations has become a focus for the development of targeted therapies for patients with MPN. JAK2 inhibitors now represent a standard of clinical care for certain forms of MPN […]
Patients are Asking – MPN Expert Dr. Andrew Kuykendall Episode 2 of 3 Update on MPN Clinical Trials and new drugs in development for 2021 and beyond. The PDUFA date is the end of the review period, where the FDA has to make a decision or respond to a New Drug Application (NDA) or a […]
by Lou Ann Donovan When you are living with a myeloproliferative neoplasm (MPN), fatigue is the most frequent symptom discussed among fellow patients. One minute you are feeling great then suddenly you feel so tired that you need to take a nap. Dealing with constant fatigue can affect your ability to complete daily tasks such […]
What are Clinical Trials? by Lou Ann Donovan Clinical trials also called interventional clinical studies involve research using participants. Through clinical trials, doctors find new ways to improve treatments and quality of life for people diagnosed with a type of blood cancer Myeloproliferative Neoplasms (MPNs). The participants receive specific interventions, such as drugs according to […]
10 Year Anniversary – Blood Cancer Awareness Month 2020 by Lou Ann Donovan National Blood Cancer Awareness Month was designated in September 2010 by the U.S. Congress. The purpose of Blood Cancer Awareness Month is to bring attention to all blood cancers, including chronic blood cancers known as Myeloproliferative Neoplasms or MPNs. Every three minutes […]
Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives Hans C. Hasselbalch, Vibe Skov, Lasse Kjær, Torben L. Sørensen, Christina Ellervik & Troels Wienecke Journal of Neuroinflammation volume 17, Article number: 248 (2020) Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or […]
Authors: Morten Orebo Holmström, Sabrina Cordua, Vibe Skov, Lasse Kjær, Niels Pallisgaard, Christina Ellervik, Hans Carl Hasselbalch, Mads Hald Andersen Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer Abstract There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this […]
Slower walking pace linked to a higher likelihood of death and hospital visits; Researchers say gait speed should be used along with other vital signs to better tailor care (WASHINGTON, June 5, 2019) — How slow—or fast—older individuals with blood cancers are able to walk four meters (about 13 feet) holds critical information about their […]
by Scott Sanders (guest author) A cancer diagnosis is devastating but it isn’t a death sentence (in most cases). Myeloproliferative Neoplasms, MPNs, are treatable and with self-care, the long-term impact on your daily life can be reduced. Taking care of your body and mind is essential to surviving and living well. Slow down One of […]
Site by: Kaleidoscopic
